Vaxart, Inc. (VXRT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VXRT currently has 241M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.78% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 240.6M shares outstanding |
240M | 0 |
| Apr 17, 2026 |
8-K filing: Vaxart, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $25.0 million of the Company's common stock over a 24-month period, and issued 447,067 commitment shares to Lincoln Park. |
230M | 590K |
| Nov 13, 2025 |
10-Q filing | 228.9M shares outstanding |
230M | 590K |
| Nov 05, 2025 |
8-K filing: Vaxart, Inc. entered into an Exclusive License and Collaboration Agreement with Dynavax Technologies Corporation, including Dynavax's agreement to purchase $5 million of Vaxart's common stock at $0.45 per share. ($5.0M proceeds) |
230M | 1.1M |
| Aug 13, 2025 |
10-Q filing | 228.4M shares outstanding |
230M | 1.1M |
| May 13, 2025 |
10-Q filing | 227.9M shares outstanding |
230M | 1.6M |
| Mar 20, 2025 |
10-K filing | 227.8M shares outstanding |
230M | 1.7M |
| Nov 13, 2024 |
10-Q filing | 227.5M shares outstanding |
230M | 2.1M |
| Aug 08, 2024 |
10-Q filing | 227.4M shares outstanding |
230M | 2.1M |
| May 13, 2024 |
10-Q filing | 168.8M shares outstanding |
170M | 61M |
| Mar 14, 2024 |
10-K filing | 144.8M shares outstanding |
140M | 85M |
| Jan 16, 2024 |
8-K filing: Vaxart, Inc. entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P to issue and sell 15,384,615 shares of common stock at a price of $0.65 per share, for gross proceeds of approximately $10 million, scheduled to close on or about January 18, 2024. ($10.0M proceeds) |
150M | 77M |
| Nov 02, 2023 |
10-Q filing | 152.0M shares outstanding |
150M | 77M |
| Aug 03, 2023 |
10-Q filing | 139.6M shares outstanding |
140M | 90M |
| Jun 08, 2023 |
8-K filing: Vaxart, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to issue and sell 16,000,000 shares of its common stock in an underwritten public offering, with an option for Cantor to purchase an additional 2,400,000 shares. ($13.6M proceeds) |
140M | 94M |
| May 04, 2023 |
10-Q filing | 135.2M shares outstanding |
140M | 94M |
| Mar 17, 2023 |
S-3 filing: The company is filing an S-3 to offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, debt securities and purchase contracts from time to time in one or more offerings. |
140M | 94M |
| Mar 15, 2023 |
10-K filing | 127.7M shares outstanding |
130M | 0 |
| Nov 09, 2022 |
10-Q filing | 126.9M shares outstanding |
130M | 0 |
| Aug 08, 2022 |
10-Q filing | 126.4M shares outstanding |
130M | 0 |
| May 09, 2022 |
10-Q filing | 125.8M shares outstanding |
130M | 0 |
| Feb 24, 2022 |
10-K filing | 125.6M shares outstanding |
130M | 0 |
| Nov 04, 2021 |
10-Q filing | 125.3M shares outstanding |
130M | 0 |
| Aug 05, 2021 |
10-Q filing | 122.8M shares outstanding |
120M | 0 |
| Jun 21, 2021 |
8-K filing: Acceleration of vesting of 100,000 option shares granted to Dr. Latour and extension of the exercisability period of vested stock options held by Dr. Latour in exchange for his release of claims against the Company and agreement to cooperate in certain matters. |
120M | 0 |
| May 06, 2021 |
10-Q filing | 118.0M shares outstanding |
120M | 0 |
| Feb 25, 2021 |
10-K filing | 117.8M shares outstanding |
120M | 0 |
| Nov 12, 2020 |
10-Q filing | 109.5M shares outstanding |
110M | 0 |
| Aug 06, 2020 |
10-Q filing | 109.2M shares outstanding |
110M | 0 |
| May 12, 2020 |
10-Q filing | 74.2M shares outstanding |
74M | 0 |
| Mar 19, 2020 |
10-K filing | 70.7M shares outstanding |
71M | 0 |